Cancer remains a significant risk to human health. Nanomedicine is a new multidisciplinary
field that is garnering a lot of interest and investigation. Nanomedicine shows great potential …

The appearance and growth of malignant tumors is a complicated process that is regulated
by a number of genes. In recent years, studies have revealed that the transforming growth …

Background Combined therapy with dabrafenib plus trametinib was approved in several
countries for treatment of BRAF V600E-mutant anaplastic thyroid cancer (ATC) based on an …

Increasing evidence has indicated a close association between immune infiltration in cancer
and clinical outcomes. However, related research in thyroid cancer is still deficient. Our …

M2‑like tumour‑associated macrophages (TAMs) have been demonstrated to promote the
growth of anaplastic thyroid carcinoma (ATC). However, the underlying mechanism of M2 …

Thyroid cancer (TC) is the most prevalent endocrine malignant tumor. Surgery,
chemotherapy, radiotherapy, and radioactive iodine (RAI) therapy are the standard TC …

The Kirsten rat sarcoma viral oncogene homolog (RAS)/v-raf-1 murine leukemia viral
oncogene homolog 1 (RAF)/mitogen-activated protein kinase 1 (MAPK) signaling cascade is …

Thyroid cancer comprises different clinical and histological entities. Whereas differentiated
(DTCs) malignancies are sensitive to radioiodine therapy, anaplastic (ATCs) and medullary …

Thyroid cancer is the most common endocrine malignant tumor, and its incidence has
increased significantly in the past few years. A growing number of noncoding RNAs …

Background The programmed cell death-1 (PD-1) receptor and its ligands PD-L1 and PD-L2
are immune checkpoints that suppress anti-cancer immunity. Typically, cancer cells express …